Ruma Rajbhandari
Gastroenterology · Boston, MANPI 1003008244
Payments from drug & device makers
Across 124 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braintree Laboratories, Inc.$617
- AbbVie$559
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$406
- Takeda Pharmaceuticals U.S.A., Inc.$405
- Gilead$186
- Bristol Myers Squibb$124
- plus $431 from 12 others
What the payments were for
- Food & beverage$2,17480%
- Education$151%
- Gifts$53920%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braintree Laboratories, Inc. | 21 | $617 |
| AbbVie | 29 | $559 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $406 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $405 |
| Gilead | 10 | $186 |
| Bristol Myers Squibb | 6 | $124 |
| Ferring Pharmaceuticals Inc. | 5 | $98 |
| Pfizer | 4 | $91 |
| Ironwood Pharmaceuticals, Inc | 2 | $49 |
| Intercept Pharmaceuticals, Inc. | 2 | $41 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Alfasigma USA, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Echosens North America, Inc. | 1 | $17 |
| Covidien LP | 1 | $16 |
| UCB, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,728 in reported general payments places this provider in the 60th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 95 | $1,396 |
| Omeprazole | 21 | $423 |
| Famotidine | 18 | $204 |
| Spironolactone | 12 | $81 |
| Furosemide | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boston
- Ramnik XavierBoston$14.3M
- Scott SnapperBoston$4.9M
- Jessica AllegrettiBoston$3.3M
- John LeungBoston$2.8M
- Michael DouganBoston$2M
- Raymond ChungBoston$1.4M
- Kathleen CoreyBoston$1.4M
- Joshua KorzenikBoston$1.2M
- Hiroyuki AiharaBoston$988K
- Carlo TraversoBoston$987K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.